Survivorship Care for Lung Cancer
(KYLEADSII Trial)
Trial Summary
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
What data supports the effectiveness of the treatment Enhanced Usual Care, Duphalac, Kristalose, Kentucky LEADS Collaborative Lung Cancer Survivorship Care Program, KLCLCSC, Kentucky LEADS Collaborative Lung Cancer Survivorship Care Program for lung cancer?
Research shows that survivorship care planning (SCP) can improve health outcomes for cancer survivors, including those with lung cancer. The implementation of SCPs has been supported by both clinicians and patients, indicating their potential effectiveness in improving long-term care and follow-up compliance.12345
How is the Kentucky LEADS Collaborative Lung Cancer Survivorship Care Program treatment different from other treatments for lung cancer?
The Kentucky LEADS Collaborative Lung Cancer Survivorship Care Program is unique because it focuses on survivorship care planning, which includes creating personalized care plans for patients who have completed primary cancer treatment. This approach emphasizes long-term follow-up and management of both physical and psychosocial effects of cancer, aiming to improve overall quality of life for lung cancer survivors.12367
What is the purpose of this trial?
The overarching goal of the Kentucky LEADS Collaborative Lung Cancer Survivorship Care program is to reduce the burden of lung cancer by offering an innovative survivorship care approach that improves lung cancer quality of life, overcomes lung cancer stigma, and helps survivors engage with care. The project involves a two-group parallel randomized clinical trial comparing the impact of the Kentucky LEADS Collaborative Lung Cancer Survivorship Care program (KLCLCSC) among lung cancer survivors (N=300) against an enhanced usual care condition (bibliotherapy+assessment) on quality of life outcomes.
Research Team
Jerod L Stapleton, PhD
Principal Investigator
University of Kentucky
Jamie L Studts, PhD
Principal Investigator
University of Colorado School of Medicine
Eligibility Criteria
This trial is for adults over 18 who have been diagnosed with lung cancer and live in a rural area (RUC code of 4+). They must be able to communicate in English. There's no mention of specific exclusions, so it seems open to many lung cancer survivors.Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive the Kentucky LEADS Collaborative Lung Cancer Survivorship Care Program (KLCLCSC) or Enhanced Usual Care (EUC) for 6 months
Follow-up
Participants are monitored for changes in quality of life, engagement, and other outcomes after treatment
Treatment Details
Interventions
- Enhanced Usual Care
- Kentucky LEADS Collaborative Lung Cancer Survivorship Care Program
Kentucky LEADS Collaborative Lung Cancer Survivorship Care Program is already approved in United States for the following indications:
- Lung cancer survivorship care
Find a Clinic Near You
Who Is Running the Clinical Trial?
Jerod L Stapleton, PhD
Lead Sponsor
University of Colorado, Denver
Lead Sponsor
G02 for Lung Cancer
Collaborator
National Cancer Institute (NCI)
Collaborator
University of Kentucky
Collaborator
University of Louisville
Collaborator